For in vitro diagnostic use. Nucleus Others Progesterone Receptor 1E2 CONFIRM IVD Breast CONFIRM anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody RTD000801 Rabbit 1E2 05278392001 CONFIRM ANTI-PR (1E2) 250 CONFIRM anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody 04015630972203 Reagents, kits 790-4296 250 tests Not Available true 05277990001 CONFIRM ANTI-PR (1E2) CONFIRM anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody 04015630972180 Reagents, kits 790-2223 50 tests Not Available true CONFIRM anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal (IgG) Primary Antibody ist für den Laboreinsatz zum qualitativen Nachweis von Progesteronrezeptor(PR)-Antigen in Schnitten von formalinfixiertem, paraffineingebettetem Gewebe auf einem VENTANA Färbeautomaten mit VENTANA-Nachweiskits und Hilfsreagenzien bestimmt. CONFIRM anti-PR (1E2) ist gegen ein Epitop im humanen Progesteronrezeptorprotein im Zellkern PR-positiver normaler und neoplastischer Zellen gerichtet. CONFIRM anti-PR (1E2) ist zur Unterstützung bei der Behandlung, Prognose und Vorhersage des Erfolgs einer Hormontherapie bei Mammakarzinom bestimmt.Dieses Produkt muss von einem qualifizierten Pathologen in Verbindung mit histologischen Untersuchungen, klinisch relevanten Informationen und geeigneten Kontrollen interpretiert werden.Verschreibungspflichtig.Dieser Antikörper ist für die Verwendung in der In-vitro-Diagnostik (IVD) bestimmt. de CONFIRM anti-PR (1E2) antibody binds to PR in formalin-fixed, paraffin embedded (FFPE) tissue sections. The specific antibody can be localized by either a biotin conjugated secondary antibody formulation that recognizes rabbit immunoglobulins, followed by the addition of a streptavidin horseradish peroxidase (HRP) conjugate (iVIEW DAB Detection Kit) or a secondary antibody-HRP conjugate (ultraView Universal DAB Detection Kit). The specific antibody-enzyme complex is then visualized with a precipitating enzyme reaction product.Clinical cases should be evaluated within the context of the performance of appropriate controls. Ventana Medical Systems, Inc. (Ventana) recommends the inclusion of a positive tissue control fixed and processed in the same manner as the patient specimen (for example, a weakly positive breast carcinoma or uterus). In addition to staining with CONFIRM anti-PR (1E2) antibody, a second slide should be stained with CONFIRM Negative Control Rabbit Ig. For the test to be considered valid, the positive control tissue should exhibit nuclear staining of the tumor cells or uterine glands and stroma. These components should be negative when stained with CONFIRM Negative Control Rabbit Ig. In addition, it is recommended that a negative tissue control slide (for example, a PR negative breast carcinoma) be included for every batch of samples processed and run on the BenchMark IHC/ISH instrument. This negative tissue control should be stained with CONFIRM anti-PR (1E2) antibody to ensure that the antigen enhancement and other pretreatment procedures did not create false positive staining. en